We are developing a therapy that can stop the loss of vision caused by glaucoma and provide the first-ever personalized care for patients.
Camras Vision is an ophthalmic medical device company developing a patented new technology for the 67 million glaucoma sufferers. Ophthalmologists are faced with limited surgical treatments due to their instability and unpredictability in controlling glaucoma. As a result, 1 out of 10 patients still lose their vision even when properly treated. Camras Vision wishes to address these problems with their device, the Camras Shunt.
Roberto AlfaroPresidentUnconfirmedRoberto Alfaro’s previous experience as a Manager for Deloitte has given him detailed knowledge in developing and improving operational processes, managing a multi-billion dollar project, selling clients new services, and managing projects domestically and internationally. While in graduate school at Duke University, he has consulted to start-ups in the biomedical and tech industries.
Lucinda CamrasChief Scientific OfficerUnconfirmedLucinda Camras has been working in aqueous humor dynamics and biomedical engineering for almost a decade. She has five patents issued or pending in the ophthalmology field. She also served as the Dir. of Scientific Research at ACE Vision Group, a start-up ophthalmic company going through clinical trials overseas. Lucinda has presented at numerous conferences, published in reputable ophthalmic journals, and received various awards.